One mission.
Five platforms. The right collaborator gets access.

Cancer won't be solved in a single lab. The science is distributed. We spent years building the platforms — and we're now placing them where the work is actually happening.

BioFund is a family office founded by seven families with one mission: to cure and prevent cancer. We work through a OneHealth approach — companion animals as the first clinical validation pathway, human therapeutics as the destination, and prevention through bioactive science as the other half of the equation. BioFund is the family office behind the mission. For years, we built and refined five research platforms for our own science. We are now opening them to mission-aligned collaborators across the United States — selectively, through relationships, one real project at a time.

We are an impact investor, not a donor. We commit our platforms first — and we look for partners who come ready to do the same when the work proves itself. Shared mission is the entry point. Shared skin in the game is where serious collaborations go.

We invest our assets where the science is real.

Five platforms built for our own research. Each collaboration begins with one — the specific one that fits your program. Not a menu, a match. Everything below was built for our own science. The right partner gets access.

01

Novel proteins & biosimilars

We produce novel proteins and biosimilars for our own oncology and OneHealth research, held in a growing Master Cell Bank. When a research program needs a protein we already carry, access comes through a joint project — no lengthy procurement, no ambiguous IP terms.

What you get

Research-grade access to specific proteins from our Master Cell Bank through a jointly structured project. Your IP stays yours. Publications by mutual agreement.

In practice A research team needed a specific reference protein to advance their oncology work. We had produced it for our own use. We opened access through a joint project. Their work moved forward.

02

Cell line engineering

When a researcher has a promising molecule and the biology is fighting back — unstable expression, insufficient yield — we engineer a stable, high-yield cell line around their molecule. The discovery is entirely theirs. We solve the biology problem that was blocking it.

What you get

A stable, high-yield, production-ready cell line engineered around your molecule. You own the cell line and everything derived from it.

In practice A researcher had a molecule with real therapeutic potential — it wouldn't express at the yield the work demanded. We built a stable cell line around it. The science that had been stalling began to move.

03

Animal health & OneHealth

Companion animals develop the same cancers humans do — spontaneously, in real bodies, on real timelines. We work with veterinary researchers whose patients need care today. The data those studies generate shortens the road to human therapeutics. One act of medicine, two beneficiaries.

What you get

A translational oncology partner for companion animal studies. Data structured from day one to inform human therapeutic development. Shared rights by agreement.

In practice Our lead therapeutic asset is entering companion animal trials first — generating real-world clinical data in a fraction of the time a conventional human-first pathway would require, while helping animals that need treatment now.

04

UFP500 Research & Product Development

We built the UFP500 platform for our own prevention research — ultra-fine particle processing that unlocks the bioactive potential of plant, marine, and agricultural materials with documented bioavailability enhancement. When there is a compelling R&D or product development question — a promising source material, a waste stream worth developing, a formulation challenge — we work on it as a co-development collaboration. We source the materials. We run the processing. We build something novel together.

What you get

A co-development partner, not a processing service. We bring the UFP500 technology, the materials sourcing, and the R&D expertise. You bring the scientific question or the product application. IP and commercial terms structured around what we build together.

In practice We identified a seafood processing waste stream — lobster shell, rich in bioactive compounds, headed for landfill. We sourced it, developed it through UFP500, and validated it as a novel research ingredient. That is the model: we find the material, we do the development, and we build the collaboration around what we create together.

05

AI-guided bioactive discovery

We built micronutri.ai for our own search for compounds that protect cells before disease takes hold. Curing cancer is one half of the mission. The other half is making sure fewer people need to be cured. If you have a discovery problem where that intelligence layer helps, we work on it with you.

What you get

Access to the micronutri.ai platform for a jointly scoped bioactive research project, structured around your specific compound or target. IP on discoveries stays with the originating researcher.

In practice micronutri.ai grew from our own prevention research — mapping the bioactive landscape to find what the science predicts will matter. The platform is open to partners whose work shares that upstream ambition.

06

Your collaboration
begins here.

The network is open.

Direct. Fast. Real.

When you work with one part of BioFund, you meet all of it.

A single collaboration opens onto the wider world of the mission — each entity a doorway to the others.

Explore the whole ecosystem at universe.biofund.org.